ApprovalTrail

Approval · Notice of Compliance 28080 · 2022

VALSARTAN: Notice of Compliance 28080

Issued May 2, 2022

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
28080
Date
May 2, 2022
Company
Sivem Pharmaceuticals UlcSaint-Laurent, Quebec, Canada
Product type
Prescription Pharmaceutical
Submission
Abbreviated New Drug Submission (ANDS)
Submission class
Admin
Reason
Administrative: Licensing Agreement Between Two Companies
Canadian reference product
DIOVAN (Novartis Pharmaceuticals Canada Inc.)

Products in this notice

BrandDINStatus today
VALSARTAN02384523Marketed
VALSARTAN02384531Marketed
VALSARTAN02384558Marketed
VALSARTAN02384566Marketed

Medicinal ingredients